How PCSK9 Controls Cholesterol—and Why It Matters

A Protein That Decides Your Cholesterol's Fate

Deep inside your liver cells, a protein called PCSK9 quietly decides how much "bad" LDL cholesterol lingers in your bloodstream. It does this not by making cholesterol, but by destroying the receptors that remove it. Understanding how this single protein works has transformed cardiovascular medicine—and opened the door to a new generation of cholesterol-lowering drugs.

What Is PCSK9?

PCSK9 stands for proprotein convertase subtilisin/kexin type 9. It is a serine protease—essentially a molecular scissors—produced mainly in the liver. Scientists discovered it in 2003 when Nabil Seidah at the Clinical Research Institute of Montreal identified a novel gene on chromosome 1. Almost simultaneously, Catherine Boileau's team in Paris linked mutations in that same gene to families with dangerously high cholesterol. The connection was clear: PCSK9 was a major, previously unknown player in lipid metabolism.

How PCSK9 Controls Cholesterol

Your body removes LDL cholesterol from the blood using LDL receptors (LDLRs) on the surface of liver cells. These receptors grab LDL particles, pull them inside the cell, and break them down. Normally, the receptor then recycles back to the cell surface to catch more cholesterol—a continuous cleanup cycle.

PCSK9 disrupts this cycle. When it binds to an LDL receptor, the entire complex—receptor and cholesterol particle together—gets pulled into the cell and routed to lysosomes for destruction. The receptor is degraded instead of recycled. Fewer receptors on the surface means less LDL gets cleared, and cholesterol levels in the blood rise.

Think of it like a parking garage: LDL receptors are the parking spaces, and LDL particles are the cars. PCSK9 demolishes parking spaces. Fewer spaces mean more cars circling the streets—more cholesterol in your blood.

Why Some People Have Naturally Low Cholesterol

Genetics proved the concept before any drug existed. People born with loss-of-function mutations in PCSK9 have unusually low LDL cholesterol throughout their lives—and dramatically lower rates of heart disease. Conversely, those with gain-of-function mutations overproduce PCSK9, have too few LDL receptors, and develop severe hypercholesterolemia, often suffering heart attacks at a young age.

This natural experiment gave researchers confidence that blocking PCSK9 would be both effective and safe—nature had already run the trial across generations.

PCSK9 Inhibitors: A New Class of Drugs

In 2015, the FDA approved the first PCSK9 inhibitors: alirocumab (Praluent) and evolocumab (Repatha). Both are monoclonal antibodies—lab-made proteins injected every two to four weeks that intercept PCSK9 before it can latch onto LDL receptors. The result: more receptors survive, more LDL gets cleared, and cholesterol drops by 50–60% on average.

Clinical trials showed these drugs reduce the risk of heart attack by approximately 27%, making them a powerful option for patients who cannot tolerate statins or whose cholesterol remains stubbornly high despite other treatments.

The Next Generation

Science has not stopped at antibodies. Inclisiran, approved in the EU and U.S., is a small interfering RNA (siRNA) that silences the PCSK9 gene inside cells, requiring only two injections per year. Researchers at the University of Barcelona recently demonstrated that polypurine hairpin DNA molecules can reduce PCSK9 protein levels by 87% in lab studies, cutting cholesterol by nearly half in mice with a single injection. Meanwhile, gene-editing approaches using base editing aim to permanently switch off PCSK9 production—a potential one-time cure for high cholesterol.

Why It Matters

Heart disease remains the world's leading cause of death, and high LDL cholesterol is one of its most treatable risk factors. For decades, statins were the only major weapon. PCSK9's discovery opened an entirely new front—one that works through a fundamentally different mechanism and can help the millions of patients for whom statins are not enough. As next-generation therapies move from lab to clinic, PCSK9 may prove to be one of the most consequential molecular targets in modern medicine.